Mauricio Pineda‐Roman

6.7k total citations · 2 hit papers
58 papers, 4.1k citations indexed

About

Mauricio Pineda‐Roman is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Mauricio Pineda‐Roman has authored 58 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 36 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Mauricio Pineda‐Roman's work include Multiple Myeloma Research and Treatments (49 papers), Protein Degradation and Inhibitors (20 papers) and Cancer Treatment and Pharmacology (8 papers). Mauricio Pineda‐Roman is often cited by papers focused on Multiple Myeloma Research and Treatments (49 papers), Protein Degradation and Inhibitors (20 papers) and Cancer Treatment and Pharmacology (8 papers). Mauricio Pineda‐Roman collaborates with scholars based in United States and China. Mauricio Pineda‐Roman's co-authors include Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Guido Tricot, Klaus Hollmig, John Crowley, Maurizio Zangari, Elias Anaissie, Joshua Epstein and Fenghuang Zhan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Mauricio Pineda‐Roman

54 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The molecular classification of multiple myeloma

2006 783 citations Fenghuang Zhan, Yongsheng Huang et al. Blood profile →
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mauricio Pineda‐Roman United States	22	3.3k	3.1k	1.8k	390	318	58	4.1k
Klaus Hollmig United States	21	3.2k 1.0×	2.7k 0.9×	1.6k 0.9×	393 1.0×	192 0.6×	48	3.7k
Jean‐Luc Harousseau France	20	2.6k 0.8×	2.2k 0.7×	1.6k 0.9×	425 1.1×	105 0.3×	45	3.4k
Carla S. Wilson United States	21	2.8k 0.9×	2.3k 0.7×	1.7k 0.9×	736 1.9×	235 0.7×	37	4.3k
Salomon Manier France	29	1.9k 0.6×	2.1k 0.7×	1.3k 0.7×	366 0.9×	719 2.3×	158	3.4k
A. Keith Stewart Canada	37	1.8k 0.6×	2.4k 0.8×	1.4k 0.8×	463 1.2×	172 0.5×	100	3.9k
Lotfi Benboubker France	26	3.0k 0.9×	2.7k 0.9×	2.0k 1.1×	571 1.5×	63 0.2×	101	3.7k
Thomas Pabst Switzerland	30	2.5k 0.8×	1.6k 0.5×	1.2k 0.7×	713 1.8×	371 1.2×	180	4.3k
Dixie‐Lee Esseltine United States	22	2.5k 0.8×	2.3k 0.7×	1.6k 0.9×	406 1.0×	98 0.3×	38	3.2k
Hareth Nahi Sweden	30	2.0k 0.6×	1.6k 0.5×	1.5k 0.9×	437 1.1×	132 0.4×	143	3.0k
Paula Rodríguez‐Otero Spain	29	2.0k 0.6×	1.7k 0.6×	1.7k 1.0×	284 0.7×	388 1.2×	181	3.4k

Countries citing papers authored by Mauricio Pineda‐Roman

Since Specialization

Citations

This map shows the geographic impact of Mauricio Pineda‐Roman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauricio Pineda‐Roman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauricio Pineda‐Roman more than expected).

Fields of papers citing papers by Mauricio Pineda‐Roman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauricio Pineda‐Roman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauricio Pineda‐Roman. The network helps show where Mauricio Pineda‐Roman may publish in the future.

Co-authorship network of co-authors of Mauricio Pineda‐Roman

This figure shows the co-authorship network connecting the top 25 collaborators of Mauricio Pineda‐Roman. A scholar is included among the top collaborators of Mauricio Pineda‐Roman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauricio Pineda‐Roman. Mauricio Pineda‐Roman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ehsan, Hamid, Myra Robinson, Peter M. Voorhees, et al.. (2024). Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life. 14(3). 384–384. 2 indexed citations

Bhutani, Manisha, Myra Robinson, David Foureau, et al.. (2024). MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Advances. 9(3). 507–519. 3 indexed citations

Symanowski, James T., David Foureau, Manisha Bhutani, et al.. (2024). Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel. Blood. 144(Supplement 1). 7027–7027.

Bhutani, Manisha, David Foureau, Myra Robinson, et al.. (2023). A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. Clinical Lymphoma Myeloma & Leukemia. 23(7). 535–544.e1. 2 indexed citations

Moore, Donald C., et al.. (2020). Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure. Clinical Lymphoma Myeloma & Leukemia. 20(7). e395–e398. 4 indexed citations

Bhutani, Manisha, Jiaxian He, Shebli Atrash, et al.. (2020). Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood. 136(Supplement 1). 38–39. 6 indexed citations

Pineda‐Roman, Mauricio, Bart Barlogie, Elias Anaissie, et al.. (2008). High‐dose melphalan‐based autotransplants for multiple myeloma. Cancer. 112(8). 1754–1764. 11 indexed citations

Zangari, Maurizio, Frits van Rhee, Elias Anaissie, et al.. (2008). Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. British Journal of Haematology. 141(4). 433–444. 28 indexed citations

Barlogie, Bart, E. Anaissie, Frits van Rhee, et al.. (2008). Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2. Journal of Clinical Oncology. 26(15_suppl). 8516–8516. 5 indexed citations

10.

Pineda‐Roman, Mauricio, Maurizio Zangari, Jeff Haessler, et al.. (2008). Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology. 140(6). 625–634. 125 indexed citations

11.

Pineda‐Roman, Mauricio, Maurizio Zangari, Frits van Rhee, et al.. (2008). VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 22(7). 1419–1427. 99 indexed citations

12.

Barlogie, Bart, Elias Anaissie, Jeffrey Haessler, et al.. (2008). Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 113(2). 355–359. 90 indexed citations

13.

Haessler, Jeffrey, John D. Shaughnessy, Fenghuang Zhan, et al.. (2007). Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research. 13(23). 7073–7079. 75 indexed citations

14.

Shaughnessy, John D., Jeffrey Haessler, Frits van Rhee, et al.. (2007). Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. British Journal of Haematology. 137(6). 530–536. 38 indexed citations

15.

Pineda‐Roman, Mauricio, et al.. (2007). Coccidioides immitis fungemia: Clinical features and survival in 33 adult patients. Heart & Lung. 36(1). 64–71. 19 indexed citations

16.

Zhan, Fenghuang, Bart Barlogie, Yongsheng Huang, et al.. (2006). A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. Blood. 108(11). 3393–3393. 12 indexed citations

17.

Shaughnessy, John D., Jeffrey Haessler, Yongsheng Huang, et al.. (2006). An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.. Blood. 108(11). 3389–3389. 6 indexed citations

18.

Barlogie, Bart, Maurizio Zangari, Vanessa Bolejack, et al.. (2006). Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma. Clinical Lymphoma & Myeloma. 6(6). 469–474. 10 indexed citations

19.

Zhan, Fenghuang, Bart Barlogie, Yongsheng Huang, et al.. (2006). Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 109(4). 1692–1700. 287 indexed citations

20.

Pineda‐Roman, Mauricio, et al.. (1998). Coccidioidomycosis: An Update. Hospital Practice. 33(9). 105–120. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact